Cardiopulmonary bypass, inflammation and how to defy it: Focus on pharmacological interventions

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 3, 2012, Pages 705-714

  Dabbagh, Ali ^a   Rajaei, Samira ^b   Monfared, Ayad Bahadori ^a   Keramatinia, Ali Asghar ^a   Omidi, Korosh ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory method; Cardiopulmonary; Inflammation; Pharmacological; Technical strategies

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; AMINOCAPROIC ACID; ANESTHETIC AGENT; ANTIOXIDANT; APROTININ; ASCORBIC ACID; ERYTHROPOIETIN; GLUCOCORTICOID; GLYCOSAMINOGLYCAN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KALLIKREIN; MAGNESIUM SULFATE; MANNITOL; MILRINONE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PEXILIZUMAB; PHOSPHODIESTERASE INHIBITOR; PLASMIN; TRANEXAMIC ACID; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CELLULAR IMMUNITY; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; OXIDATIVE STRESS; REPERFUSION INJURY;

EID: 84865200447     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Paparella D, Yau TM and Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothorac. Surg. (2002) 21: 232-44.
2. Ferasatkish R, Dabbagh A, Alavi M, Mollasadeghi G, Hydarpur E, Moghadam AA, Faritus ZS and Totonchi MZ. Effect of magnesium sulfate on extubation time and acute pain in coronary artery bypass surgery. Acta Anaesthesiol. Scand. (2008) 52: 1348-52.
3. Dabbagh A, Rajaei S and Shamsolahrar MH. The effect of intravenous magnesium sulfate on acute postoperative bleeding in elective coronary artery bypass surgery. J. Perianesth. Nurs. (2010) 25: 290-5.
4. Murphy GS, Hessel EA and Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. Anesth. Analg. (2009) 108: 1394-417.
5. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW and Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J. Cardiothorac. Vasc. Anesth. (2009) 23: 223-31.
6. Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW and Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J. Cardiothorac. Vasc. Anesth. (2009) 23: 384-93.
7. Patel JA and Ghatak SB. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review. Recent Pat. Cardiovasc. Drug Discov. (2008) 3: 145-52.
8. Miller BE and Levy JH. The inflammatory response to cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (1997) 11: 355-66.
9. Lante W, Franke A, Weinhold C and Markewitz A. Immunoglobulin levels and lymphocyte subsets following cardiac operations: further evidence for a T-helper cell shifting. Thorac. Cardiovasc. Surg. (2005) 53: 16-22.
10. Wan S, LeClerc JL and Vincent JL. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann. Thorac. Surg. (1997) 63: 269-76.
11. Rimmelé T, Venkataraman R, Madden NJ, Elder MM, Wei LM, Pellegrini RV and Kellum JA. Comparison of inflammatory response during on-pump and off-pump coronary artery bypass surgery. Int. J. Artif. Organs (2010) 33: 131-8.
12. Karu I, Tähepõld P, Sulling TA, Alver M, Zilmer M and Starkopf J. Off-pump coronary surgery cause immediate release of myocardial damage markers. Asian Cardiovasc. Thorac. Ann. (2009) 17: 494-9.
13. Serrano CV Jr, Souza JA, Lopes NH, Fernandes JL, Nicolau JC, Blotta MH, Ramires JA and Hueb WA. Reduced expression of systemic proinflammatory and myocardial biomarkers after off-pump versus on-pump coronary artery bypass surgery: a prospective randomized study. J. Crit. Care (2010) 25: 305-12.
14. Dietrich W. Aprotinin: 1 year on. Curr. Opin. Anaesthesiol. (2009) 22: 121-7.
15. Baden H, Jordal K, Lund F and Zachariae F. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir. Scand. Suppl. (1967) 378: 97-102.
16. Olsen GB and Williams HT. Acute hemorrhagic necrosis of the pancreas of the dog and its suppression with Trasylol. Can. J. Surg. (1966) 9: 415-9.
17. Hashimoto D, Ohmuraya M, Wang J, Yamamura K, Hirota M and Baba H. Effect of low-molecular weight trypsin inhibitor, nafamostat mesilate, on trypsin activity using the pancreatic acinar cells. Pancreas (2009) 38: 595-7.
18. Alonso A, Whitten CW and Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation. Ann. Thorac. Surg. (1999) 67: 392-5.
19. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M and Wells G, Clinch J and Pretorius R. BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med. (2008) 358: 2319-31.
20. Bidstrup BP, Royston D, Sapsford RN and Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J. Thorac. Cardiovasc. Surg. (1989) 97: 364-72.
21. Bidstrup BP, Royston D, Taylor KM and Sapsford RN. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery. Lancet (1988) 1: 366-7.
22. Fergusson D, Glass KC, Hutton B and Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin. Trials (2005) 2: 218-29.
23. Beattie WS and Karkouti K. Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth. Analg. (2006) 103: 1360-4.
24. Karkouti K and Beattie WS. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: no. J. Thromb. Haemost. (2006) 4: 1879-81.
25. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L and Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion (2006) 46: 327-38.
26. Mangano DT, Tudor IC and Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. (2006) 354: 353-65.
27. Mangano DT, Rieves RD and Weiss KD. Judging the safety of aprotinin. N. Engl. J. Med. (2006) 355: 2261-2.
28. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C and Levin J. Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA (2007) 297: 471-9.
29. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ and Blackstone EH. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit. Care Med. (2006) 34: 1608-16.
30. Takagi H, Manabe H, Kawai N, Goto SN and Umemoto T. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials. Interact. Cardiovasc. Thorac. Surg. (2009) 9: 98-101.
31. Augoustides JG. Perioperative safety of aprotinin in coronary artery bypass graft surgery: is there life after BART? Drug Saf. (2008) 31: 557-60.
32. Murkin JM. Lessons learned in antifibrinolytic therapy: The BART trial. Semin. Cardiothorac. Vasc. Anesth. (2009) 13: 127-31.
33. Henry D, Carless P, Fergusson D and Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ (2009) 180: 183-93.
34. Ide M, Bolliger D, Taketomi T and Tanaka KA. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J. Anesth. (2010) 24: 96-106.
35. Hill GE, Alonso A, Spurzem JR, Stammers AH and Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J. Thorac. Cardiovasc. Surg. (1995) 110: 1658-62.
36. Anti-inflammatory effect of aprotinin: a meta-analysis. J. Extra Corpor. Technol. (2009) 41: 79-86.
37. Landis C. Pharmacologic strategies for combating the inflammatory response. J. Extra Corpor. Technol. (2007) 39: 291-5.
38. Robertson-Malt S, Afrane B, El Barbary M. Prophylactic steroids for pediatric open heart surgery. Cochrane Database Syst. Rev. (2007) 17: CD005550.
39. Chaney MA. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest (2002) 121: 921-31.
40. Baker WL, White CM, Kluger J, Denowitz A, Konecny CP and Coleman CI. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm. (2007) 4: 461-8.
41. Marik PE and Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J. Crit. Care (2009) 24: 458-63.
42. Raja SG and Dreyfus GD. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc. Thorac. Ann. (2005) 13: 382-95.
43. Yasser Mohamed, Elmistekawy E and El-Serogy H. Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass. Semin. Cardiothorac. Vasc. Anesth. (2009) 13: 231-7.
44. Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM and Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J. Cardiothorac. Vasc. Anesth. (2011) 25: 156-65.
45. Bezuhly M, Liwski R, West KA and Morris SF. Activated protein C: an emerging therapeutic agent in the prevention of ischemia-reperfusion injury. J. Reconstr. Microsurg. (2008) 24: 361-7.
46. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM and Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury-a review. J. Surg. Res. (2008) 150: 304-30.
47. Sadat U. Signaling pathways of cardioprotective ischemic preconditioning. Int. J. Surg. (2009) 7: 490-8.
48. Prabhu A, Sujatha DI, Ninan B and Vijayalakshmi MA. Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann. Vasc. Surg. (2010) 24: 525-31.
49. Lanzarone E, Gelmini F, Fumero A, Carini M, Costantino ML, Fumero R and Alfieri O. Preservation of endothelium nitric oxide release during beating heart surgery with respect to continuous flow cardiopulmonary bypass. Perfusion (2010) 25: 57-64.
50. Veglia F, Werba JP, Tremoli E, Squellerio I, Sisillo E, Parolari A, Minardi F and Cavalca V. Assessment of oxidative stress in coronary artery bypass surgery: comparison between the global index OXY-SCORE and individual biomarkers. Biomarkers (2009) 14: 465-72.
51. Collard CD and Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology (2001) 94: 1133-8.
52. Yeh CH, Chen TP, Wang YC, Lin YM and Fang SW. Cardiomyocytic apoptosis limited by bradykinin via restoration of nitric oxide after cardioplegic arrest. J. Surg. Res. (2010) 163: e1-9.
53. Borowski A, Kurt M, Calvo S, Paprotny G, Godehardt E, Fraessdorf J and Ghodsizad A. Metabolic monitoring of postischemic myocardium during intermittent warm-blood cardioplegic administration. Tex. Heart Inst. J. (2010) 37: 184-8.
54. Schwartz SM, Duffy JY, Pearl JM and Nelson DP. Cellular and molecular aspects of myocardial dysfunction. Crit. Care Med. (2001) 29: S214-9.
55. Ustunsoy H, Sivrikoz MC, Tarakcioglu M, Bakir K, Guldur E and Celkan MA. The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J. Card. Surg. (2006) 21: 57-61.
56. Hamamoto M, Suga M, Takahashi Y, Sato Y, Inamori S, Yagihara T, Nakatani T and Kitamura S. Suppressive effect of phosphodiesterase type 4 inhibitions on systemic inflammatory responses after cardiopulmonary bypass. J. Artif. Organs (2006) 9: 144-8.
57. Chanani NK, Cowan DB, Takeuchi K, Poutias DN, Garcia LM, del Nido PJ and McGowan FX Jr. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling. Circulation (2002) 106: I284-9.
58. Yamaura K, Okamoto H, Akiyoshi K, Irita K, Taniyama T and Takahashi S. Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2001) 15: 197-203.
59. Yamaura K, Akiyoshi K, Irita K, Taniyama T and Takahashi S. Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass. Acta Anaesthesiol. Scand. (2001) 45: 427-34.
60. Möllhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD, Asfour B and Berendes E. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology (1999) 90: 72-80.
61. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE and Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. (2007) 28: 184-92.
62. Huber K, Holmes DR Jr, van't Hof AW, Montalescot G, Aylward PE, Betriu GA, Widimsky P, Westerhout CM, Granger CB and Armstrong PW. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur. Heart J. (2010) 31: 1708-16.
63. Toma M, Fu Y, Ezekowitz JA, McAlister FA, Westerhout CM, Granger CB and Armstrong PW. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. Am. Heart J. (2010) 160: 671-7.
64. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, Porto I, Andreotti F, Crea F and Banning AP. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 2008; 136(4):884-93.
65. Sonntag J, Dähnert I, Stiller B, Hetzer R and Lange PE. Complement and contact activation during cardiovascular operations in infants. Ann. Thorac. Surg. (1998) 65: 525-31.
66. Göl MK, Nisanoǧlu V, Işcan Z, Balci M, Kandemir O and Taşdemir O. Inhibition of systemic inflammatory response with sodium nitroprusside in open heart surgery. J. Cardiovasc. Surg. (Torino) (2002) 43: 803-9.
67. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, Klonisch T, Unruh H, Kashani HH, Schaafsma D, Los M and Halayko AJ. Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53. PLoS One (2011) 6: e16523.
68. Bach F, Grundmann U, Bauer M, Buchinger H, Soltész S, Graeter T, Larsen R and Silomon M. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol. Scand. (2002) 46: 1227-35.
69. Berendes E, Möllhoff T, Van Aken H, Schmidt C, Erren M, Deng MC, Weyand M and Loick HM. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth. Analg. (1997) 84: 950-7.
70. Murphy GS, Szokol JW, Marymont JH, Avram MJ and Vender JS. The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery. Anesth. Analg. (2007) 104: 1334-42.
71. Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E and Nishanian E. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. J. Cardiothorac. Vasc. Anesth. (2006) 20: 217-22.
72. Zilberstein G, Levy R, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Appelbaum A and Roytblat L. Ketamine attenuates neutrophil activation after cardiopulmonary bypass. Anesth. Analg. (2002) 95: 531-6.
73. Roytblat L, Talmor D, Rachinsky M, Greemberg L, Pekar A, Appelbaum A, Gurman GM, Shapira Y and Duvdenani A. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth. Analg. (1998) 87: 266-71.
74. Stammberger U, Hamacher J, Pache JC and Schmid RA. sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection. Eur. J. Cardiothorac. Surg. (2002) 22: 368-72.
75. Kyriakides C, Wang Y, Austen WG Jr, Favuzza J, Kobzik L, Moore FD Jr and Hechtman HB. Sialyl Lewis(x) hybridized complement receptor type 1 moderates acid aspiration injury. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 281: L1494-9.
76. Zacharowski K, Otto M, Hafner G, Marsh HC Jr and Thiemermann C. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br. J. Pharmacol. (1999) 128: 945-52.
77. Billings FT, Pretorius M, Siew ED, Yu C and Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2010) 24: 913-20.
78. Hudetz JA and Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. J. Cardiothorac. Vasc. Anesth. (2010) 24: 131-42.
79. Hudetz JA, Patterson KM, Iqbal Z, Gandhi SD, Byrne AJ, Hudetz AG, Warltier DC and Pagel PS. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2009) 23: 651-7.
80. Liu T, Li G and Xu G. Levosimendan may prevent postoperative atrial fibrillation through anti-inflammatory and antioxidant modulation. J. Cardiothorac. Vasc. Anesth. (2009) 23: 757-8.
81. Cho EJ, Yoon JH, Hong SJ, Lee SH and Sim SB. The effects of sevoflurane on systemic and pulmonary inflammatory responses after cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2009) 23: 639-45.
82. Krzych LJ, Szurlej D and Bochenek A. Rationale for propofol use in cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2009) 23: 878-85.
83. Ozturk T, Gok S and Nese N. Levosimendan attenuate reperfusion injury in an isolated perfused rat heart model. J. Cardiothorac. Vasc. Anesth. (2010) 24: 624-8.
84. Krzych L, Szurlej D and Bochenek A. Response: Is it reasonable to discourage propofol use in cardiac surgery patients until strong evidence is provided? J. Cardiothorac. Vasc. Anesth. (2011) 25: 202.
85. Poulsen TD, Andersen LW, Steinbrüchel D, Gøtze JP, Jørgensen OS and Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2009) 23: 316-23.
86. Foroughi M, Rahimian H, Dabbagh A, Majidi M, Hekmat M, Beheshti M and Shahzamani M. Postoperative n-terminal pro-brain natriuretic peptide level in coronary artery bypass surgery with ventricular dysfunction after perioperative glucose-insulin-potassium treatment. J. Cardiothorac. Vasc. Anesth. (2012) Article in Press.
87. Gunaydin S, Ucar HI, Serter T, McCusker K, Ozcelik G, Salman N and Yorgancioglu AC. Hyaluronan based heparin free coated open and closed extracorporeal circuits for high risk coronary revascularization. J. Extra Corpor. Technol. (2010) 42: 286-92.
88. Thiara AS, Andersen VY, Videm V, Mollnes TE, Svennevig K, Hoel TN and Fiane AE. Comparable biocompatibility of Phisio-and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion (2010) 25: 9-16.
89. Wagner WR, Johnson PC, Thompson KA and Marrone GC. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann. Thorac. Surg. (1994) 58: 734-40.
90. Gunaydin S, McCusker K, Sari T, Onur MA and Zorlutuna Y. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts. Interact. Cardiovasc. Thorac. Surg. (2010) 10: 371-6.
91. Gunaydin S, Farsak B, McCusker K, Vijay V, Sari T, Onur MA, Gurpinar A, Zorlutuna Y. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization. J. Cardiovasc. Med. (Hagerstown). (2009) 10: 135-42.
92. Andersson J, Larsson R, Richter R, Ekdahl KN and Nilsson B. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials (2001) 22: 2435-43.
93. Draaisma AM, Hazekamp MG, Anes N, Schoof PH, Hack CE, Sturk A and Dion RA. Phosphorylcholine coating of bypass systems used for young infants does not attenuate the inflammatory response. Ann. Thorac. Surg. (2006) 81: 1455-9.
94. Kiliç D, Gunaydin S, Kisa U, Sari T, Deveci O and Zorlutuna Y. Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe? Inflamm. Res. (2009) 58: 292-7.
95. Welsby IJ, Jones WL, Arepally G, De Lange F, Yoshitani K, Phillips-Bute B, Grocott HP, Becker R and Mackensen GB. Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. Anesthesiology (2007) 106: 295-301.
96. Nilsson B, Ekdahl KN, Mollnes TE and Lambris JD. The role of complement in biomaterial-induced inflammation. Mol. Immunol. (2007) 44: 82-94.
97. Stiller B, Sonntag J, Dähnert I, Alexi-Meskishvili V, Hetzer R, Fischer T and Lange PE. Capillary leak syndrome in children who undergo cardiopulmonary bypass: clinical outcome in comparison with complement activation and C1 inhibitor. Intensive Care Med. (2001) 27: 193-200.
98. Gunaydin S, Mccusker K and Vijay V. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits. J. Extra Corpor. Technol. (2005) 37: 290-5.
99. Valle-Giner I, Martí-Bonmatí E, Alegría-Torán A, Montero A and Morcillo EJ. Changes in alpha-tocopherol and retinol levels during cardiopulmonary bypass correlate with maximal arterial partial pressure of oxygen. Free Radic. Res. (2007) 41: 1061-7.
100. Apostolakis EE, Koletsis EN, Baikoussis NG, Siminelakis SN, Papadopoulos GS. Strategies to prevent intraoperative lung injury during cardiopulmonary bypass. J. Cardiothorac. Surg. (2010) 5: 1.
101. Li S, Price R, Phiroz D, Swan K and Crane TA. Systemic inflammatory response during cardiopulmonary bypass and strategies. J. Extra Corpor. Technol. (2005) 37: 180.
102. Lappegård KT, Fung M, Bergseth G, Riesenfeld J and Mollnes TE. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition. Ann. Thorac. Surg. (2004) 78: 38-44.
103. Day JR and Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int. J. Surg. (2005) 3: 129-40.
104. Miranda DR, Gommers D, Papadakos PJ and Lachmann B. Mechanical ventilation affects pulmonary inflammation in cardiac surgery patients: the role of the open-lung concept. J. Cardiothorac. Vasc. Anesth. (2007) 21: 279-84.
105. Eichenbaum KD and Neustein SM. Acute lung injury after thoracic surgery. J. Cardiothorac. Vasc. Anesth. (2010) 24: 681-90.
106. Raja SG and Berg GA. Impact of off-pump coronary artery bypass surgery on systemic inflammation: current best available evidence. J. Card. Surg. (2007) 22: 445-55.
107. Kunes P, Mandak J, Harrer J, Kolackova M, Andrys C, Holicka M and Krejsek J. Up-regulation of the Apo/Fas (CD95) complex on neutrophils harvested during cardiac surgery: distinct findings in patients operated on with or without the use of cardiopulmonary bypass. Perfusion (2010) 25: 41-6.
108. Elahi MM, Yii M and Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2008) 22: 455-67.
109. McFarlane HJ, MacDonald J, Collins TC, Molyneaux PJ and Carman WF. Severe pneumonia after cardiac surgery as a result of infection with parainfluenza virus type 4. J. Cardiothorac. Vasc. Anesth. (2009) 23: 84-6.
110. Schober P, Kalmanowicz M, Schwarte LA and Loer SA. Cardiopulmonary bypass increases endogenous carbon monoxide production. J. Cardiothorac. Vasc. Anesth. (2009) 23: 802-6.
111. Zangrillo A, Garozzo FA, Biondi-Zoccai G, Pappalardo F, Monaco F, Crivellari M, Bignami E, Nuzzi M and Landoni G. Miniaturized cardiopulmonary bypass improves short-term outcome in cardiac surgery: a meta-analysis of randomized controlled studies. J. Thorac. Cardiovasc. Surg. (2010) 139: 1162-9.